Review
Sep 2026
Implementing liquid biopsy in HR+/HER2- metastatic breast cancer: challenges and opportunities.
LB is progressively shifting from a research tool to a clinical decision-making instrument in HR+/HER2- mBC, and integrated multiparametric LB approaches combining CTCs and ctDNA are crucial to improve prognostic accuracy and clinical decision-making.
V. Frescura, M. Cristofanilli, C. Reduzzi et al.
· Current Opinion in Oncology · 0 citations